Scott W Grimm

Summary

Affiliation: AstraZeneca R and D

Publications

  1. doi request reprint The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America
    Scott W Grimm
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Drug Metab Dispos 37:1355-70. 2009
  2. pmc Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics
    Scott W Grimm
    AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA
    Br J Clin Pharmacol 61:58-69. 2006
  3. doi request reprint Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition
    Jian Guo
    Department of Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, Wilmington, DE 19803, USA
    J Pharm Biomed Anal 55:964-71. 2011
  4. doi request reprint In vitro and in vivo metabolism of a selective δ-opioid receptor
    Jian Guo
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19803, USA
    Drug Metab Dispos 39:1883-94. 2011
  5. doi request reprint Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells
    Diansong Zhou
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19803, USA
    Drug Metab Dispos 38:1015-8. 2010
  6. doi request reprint Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct
    Chungang Gu
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Drug Metab Dispos 40:1151-63. 2012
  7. pmc A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison
    Diansong Zhou
    Clinical Pharmacology Science DMPK Clinical Neuroscience, AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA
    Br J Clin Pharmacol 74:98-108. 2012
  8. doi request reprint In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
    Yan Li
    Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Xenobiotica 40:721-9. 2010
  9. ncbi request reprint Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions
    Diansong Zhou
    Department of Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Wilmington, DE 19810, USA
    Drug Metab Dispos 34:976-83. 2006
  10. doi request reprint Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine
    Diansong Zhou
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19803, USA
    Drug Metab Dispos 38:863-70. 2010

Detail Information

Publications13

  1. doi request reprint The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers of America
    Scott W Grimm
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Drug Metab Dispos 37:1355-70. 2009
    ....
  2. pmc Effects of cytochrome P450 3A modulators ketoconazole and carbamazepine on quetiapine pharmacokinetics
    Scott W Grimm
    AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA
    Br J Clin Pharmacol 61:58-69. 2006
    ..To explore the potential for drug interactions on quetiapine pharmacokinetics using in vitro and in vivo assessments...
  3. doi request reprint Liquid chromatography-tandem mass spectrometry method for measurement of nicotine N-glucuronide: a marker for human UGT2B10 inhibition
    Jian Guo
    Department of Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, Wilmington, DE 19803, USA
    J Pharm Biomed Anal 55:964-71. 2011
    ..IC(50) values for inhibition of nicotine N-glucuronidation by amitriptyline, imipramine, lamotrigine, and trifluoperazine were calculated. Trifluoperazine was found to be a non-substrate inhibitor for human UGT2B10...
  4. doi request reprint In vitro and in vivo metabolism of a selective δ-opioid receptor
    Jian Guo
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19803, USA
    Drug Metab Dispos 39:1883-94. 2011
    ..The structures of metabolites were elucidated by high-resolution tandem mass spectrometry. M1, M4, and M6 were the most abundant metabolites observed in rat bile. Only a low level of parent [¹⁴C]compound I was observed in rat plasma...
  5. doi request reprint Expression and characterization of dog cytochrome P450 2A13 and 2A25 in baculovirus-infected insect cells
    Diansong Zhou
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware 19803, USA
    Drug Metab Dispos 38:1015-8. 2010
    ..These results provided additional information about the selectivity of these commonly used probe substrates...
  6. doi request reprint Metabolism of a G protein-coupled receptor modulator, including two major 1,2,4-oxadiazole ring-opened metabolites and a rearranged cysteine-piperazine adduct
    Chungang Gu
    AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Drug Metab Dispos 40:1151-63. 2012
    ..These findings support a previously reported mechanism regarding glutathione detoxification for piperazine bioactivation products...
  7. pmc A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison
    Diansong Zhou
    Clinical Pharmacology Science DMPK Clinical Neuroscience, AstraZeneca Pharmaceuticals LP, Wilmington, DE 19850, USA
    Br J Clin Pharmacol 74:98-108. 2012
    ..The induction effects of AZD7325 on CYP1A2 and CYP3A4 have not been systematically studied...
  8. doi request reprint In vitro assessment of metabolic drug–drug interaction potential of AZD2624, neurokinin-3 receptor antagonist, through cytochrome P(450) enzyme identification, inhibition, and induction studies
    Yan Li
    Discovery DMPK, AstraZeneca Pharmaceuticals, Wilmington, Delaware, USA
    Xenobiotica 40:721-9. 2010
    ..However, metabolism of AZD2624 might be inhibited when co-administrated with potent CYP3A4/5 inhibitors...
  9. ncbi request reprint Comparison of methods for the prediction of the metabolic sites for CYP3A4-mediated metabolic reactions
    Diansong Zhou
    Department of Drug Metabolism and Pharmacokinetics, AstraZeneca Pharmaceuticals, Wilmington, DE 19810, USA
    Drug Metab Dispos 34:976-83. 2006
    ..The MetaSite methodology is automated, rapid, and has relatively accurate predictions compared with the docking methodology used in this study...
  10. doi request reprint Role of human UGT2B10 in N-glucuronidation of tricyclic antidepressants, amitriptyline, imipramine, clomipramine, and trimipramine
    Diansong Zhou
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19803, USA
    Drug Metab Dispos 38:863-70. 2010
    ....
  11. doi request reprint In vitro evaluation of potential drug-drug interactions with ticagrelor: cytochrome P450 reaction phenotyping, inhibition, induction, and differential kinetics
    Diansong Zhou
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals LP, 1800 Concord Pike, Wilmington, DE 19803, USA
    Drug Metab Dispos 39:703-10. 2011
    ..Although ticagrelor exhibited a tendency for CYP2B6 and CYP2C9 induction, its potential to cause drug interactions via the induction of these enzymes is low when its exposure at a therapeutic dose is considered...
  12. doi request reprint Absorption, excretion, and metabolism of a potential GABA-A α2/3 receptor modulator in rats
    Jian Guo
    Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, 1800 Concord Pike, Wilmington, DE 19803, USA
    Xenobiotica 41:385-99. 2011
    ..The structures of metabolites were elucidated by high-resolution tandem mass spectrometry. Similar metabolite profiles were observed in rats given AZD6280 orally or intravenously...
  13. doi request reprint In vitro metabolism of α7 neuronal nicotinic receptor agonist AZD0328 and enzyme identification for its N-oxide metabolite
    Diansong Zhou
    Department of Clinical Pharmacology and DMPK, AstraZeneca Pharmaceuticals, Wilmington, DE, USA
    Xenobiotica 41:232-42. 2011
    ..4. Multiple enzymes including CYP2D6, CYP3A4/5, FMO1 and FMO3 catalyzed AZD0328 metabolism. The potential for AZD0328 to be inhibited clinically by co-administered drugs or genetic polymorphism is relative low...